XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' equity (Details)
1 Months Ended 3 Months Ended
May 16, 2022
$ / shares
shares
Nov. 12, 2020
USD ($)
Feb. 28, 2023
USD ($)
$ / shares
shares
Feb. 28, 2022
USD ($)
Mar. 31, 2023
USD ($)
Vote
$ / shares
shares
Mar. 31, 2022
USD ($)
shares
Dec. 31, 2022
$ / shares
shares
Common stock              
Stock, shares authorized         440,000,000    
Common stock, shares authorized         400,000,000   400,000,000
Common stock, par value (in dollars per share) | $ / shares         $ 0.001   $ 0.001
Preferred stock, shares authorized         40,000,000    
Preferred stock, par value (in dollars per share) | $ / shares         $ 0.001    
Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering   3.00%          
Number of voting rights per common share | Vote         1    
Stock based compensation expense | $         $ 16,244 $ 2,100,000  
Shelf Registration Statement              
Maximum amount to be issued under universal shelf registration statement | $   $ 350,000,000.0          
Maximum amount to be issued under at-the-market offering program | $   $ 14,744,728          
Proceeds from issuance of common stock | $         5,788,918    
Common stock issuance costs | $         $ 648,928    
Common Stock              
Common stock              
Conversion of preferred stock into common stock (in shares)         1,446,701    
Shelf Registration Statement              
Shares issued     1,050,000        
Issue price per share | $ / shares     $ 5.25        
Proceeds from issuance of common stock | $     $ 4,900,000        
Common stock issuance costs | $       $ 600,000      
Series A Convertible Preferred Stock              
Common stock              
Conversion of preferred stock into common stock (in shares)         2,893,403    
Number of shares remained to be converted into common stock         56,227    
Atrin Pharmaceuticals, Inc | Common Stock              
Common stock              
Common stock, par value (in dollars per share) | $ / shares $ 0.001            
Issuance of stock upon acquisition of Atrin (in shares) 55,869            
Atrin Pharmaceuticals, Inc | Series A Convertible Preferred Stock              
Common stock              
Issuance of stock upon acquisition of Atrin (in shares) 2,949,630            
Preferred stock conversion ratio 10            
ATM offering              
Shelf Registration Statement              
Shares issued         26,302 0  
Proceeds from issuance of common shares | $         $ 300,000    
Common stock issuance costs | $           $ 8,000